Member Contact: Megan Baldwin
Position: CEO & Managing Director
Industry: Biotech & Pharmaceuticals
Opthea Limited (ASX:OPT) is a clinical stage biotechnology company based in Melbourne Australia developing novel therapies for the treatment of eye diseases.
Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, that cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet age-related macular degeneration (wet AMD).
Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients.
Enquiries can be directed to: email@example.com